Filing Details
- Accession Number:
- 0000899243-23-005565
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-17 20:15:16
- Reporting Period:
- 2023-02-16
- Accepted Time:
- 2023-02-17 20:15:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1631574 | Wave Life Sciences Ltd. | WVE | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1657675 | Chandra Vargeese | C/O Wave Life Sciences Ltd., 733 Concord Ave. Cambridge MA 02138 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Disposition | 2023-02-16 | 10,249 | $4.03 | 106,624 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Share Option (right to buy) | Acquisiton | 2023-02-17 | 295,400 | $0.00 | 295,400 | $4.75 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
295,400 | 2033-02-17 | No | 4 | A | Direct |
Footnotes
- On February 16, 2023, the reporting person sold 10,249 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2023. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.03 to $4.17 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- Includes 1,500 ordinary shares acquired on July 14, 2022, and 4,278 ordinary shares acquired on January 14, 2023, under the issuer's 2019 Employee Share Purchase Plan.
- The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.